3 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 4 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Clear Cell Renal Cell Carcinoma Metastatic: new trials by email Literature Review of Clear Cell Renal Cell Carcinoma Metastatic trials Research Report on Clear Cell Renal Cell Carcinoma Metastatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma NEO-811 - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Neomorph, Inc | 30 | 2025-12-19 | 2026-10-05 |
| Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients 68Ga-NYM005 injection - Clear Cell Renal Cell Carcinoma Metastatic | Phase 1 / Phase 2 | Completed | Norroy Bioscience Co., LTD | 19 | 2024-06-17 | 2025-05-21 |
| Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours CA9hu-1 - Clear Cell Renal Cell Carcinoma Metastatic, TNBC - Triple-Negative Breast Cancer | Phase 1 | Not yet recruiting | Mabpro, a.s. | 50 | 2024-01-01 | 2023-03-15 |
| The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial Cytoreductive nephrectomy±metastasectomy, Human-derived materials sampling - Kidney Cancer, Clear Cell Renal Cell Carcinoma Metastatic | Not applicable | Recruiting | Yonsei University | 40 | 2023-07-01 | 2023-06-22 |
| Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab Selenomethionine (SLM), Axitinib, Pembrolizumab - Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic | Phase 1 / Phase 2 | Active not recruiting | Mohammed Milhem | 55 | 2022-09-19 | 2025-12-10 |
Clear-cell metastatic renal cell carcinoma (6) · Carcinoma, Renal Cell (3) · Kidney Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Head and Neck Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasms, Multiple Primary (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Urologic Diseases (4) · Urologic Neoplasms (4) · Adenocarcinoma (3) · Carcinoma (3) · Kidney Neoplasms (2)
Axitinib (1) · Denosumab (1) · Diphosphonates (1) · Ibandronic Acid (1) · Radiotherapy (1) · Selenomethionine (1) · Zoledronic Acid (1) · pembrolizumab (1)
Kelly Fitzgerald, MD (1) · Mabpro, a.s. (1) · Mohammed Milhem (1) · Neomorph, Inc (1) · Norroy Bioscience Co., LTD (1) · Yonsei University (1)
United States (3) · China (1) · South Korea (1)
Kelly Fitzgerald, MD (1) · Klaus Wagner, MD, PhD (1) · Mohammed Milhem, MD (1) · Won Sik Ham (1)